Please assess the completion status of the following clinical trial:

Trial Title: Enzyme Replacement Therapy in Fabry Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 16 years and ≤ 65 years~* clinical diagnosis of Fabry disease, confirmed by α-galactosidase A assay and detection of mutation in α-GalA gene~* serum creatinine ≥ 1.4 mg/dl (females) and ≥ 1.6 mg/dl (males) and/or proteinuria ≥ 0.4 g/24h~* written informed consent~Exclusion Criteria:~* any clinically relevant condition that may affect study participation and/or study results~* inability to fully understand the purpose and the risks of the study

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Patients with Fabry disease (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).